Clinical trials recruiting in Manchester, New Hampshire

Phase breakdown

Conditions recruiting in Manchester, New Hampshire

Recruiting trials in Manchester, New Hampshire

• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
  NCT07063745 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Assessment of CCM in HF With Higher Ejection Fraction
  NCT05064709 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female)
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
  NCT05955339 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female)
• Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
  NCT06898593 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
  NCT03851445 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
  NCT06777368 · Phase: Not specified · Ages: 18 Years to 105 Years · Sex: All (male and female)
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
  NCT03723928 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
  NCT06116682 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
  NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female)
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Manchester, New Hampshire?

19 recruiting trials have at least one study site in Manchester, New Hampshire.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.